IBI311: A Comprehensive Clinical and Strategic Analysis of a Novel IGF-1R Inhibitor for Thyroid Eye Disease

The Clinical Challenge and Therapeutic Landscape of Thyroid Eye Disease (TED)

Pathophysiology and Clinical Burden of TED

Thyroid Eye Disease (TED), also known as Graves' Ophthalmopathy, is an organ-specific autoimmune disorder characterized by progressive inflammation and subsequent damage to the tissues within the orbit.[1] The condition is most frequently associated with Graves' disease, an autoimmune hyperthyroid state, and it is estimated that 25% to 50% of patients with Graves' disease will develop clinically significant TED.[1] The annual incidence of TED is markedly higher in women, estimated at 16 per 100,000, compared to 2.9 per 100,000 in men, with an overall prevalence estimated to be between 0.1% and 0.3%.[1]

The underlying pathophysiology of TED is complex, but a central mechanism involves the overexpression of the Insulin-like Growth Factor 1 Receptor (IGF-1R) on the surface of orbital fibroblasts (OFs), as well as on B and T lymphocytes that infiltrate the orbital space.[6] This overexpression sensitizes orbital tissues to autoimmune attack. Pathogenic autoantibodies, including those targeting the thyrotropin receptor (TSHR) and IGF-1R, trigger a signaling cascade within these cells. This activation of OFs leads to their proliferation and differentiation into myofibroblasts and adipocytes. The subsequent pathological processes include the excessive synthesis and accumulation of hydrophilic glycosaminoglycans (GAGs), such as hyaluronic acid, and the expansion of orbital fat and muscle volume. This tissue remodeling is the direct cause of the debilitating clinical manifestations of the disease.

Patients with TED experience a range of symptoms and signs that significantly impair visual function, physical appearance, and overall quality of life.[1] The most prominent and distressing feature is proptosis, or exophthalmos, which is the forward bulging of the eyes. Other common manifestations include diplopia (double vision) due to extraocular muscle dysfunction, periorbital edema (swelling around the eyes), ocular congestion, and photophobia (light sensitivity).[1] In its most severe forms, TED can become sight-threatening, leading to complications such as compressive optic neuropathy or exposure keratopathy and corneal ulceration resulting from the inability to close the eyelids over the proptotic globes.[1]

Current Treatment Paradigm and Unmet Needs in China

The current standard of care for moderate-to-severe, active TED in many regions, including China, has historically been limited. Intravenous glucocorticoid therapy is typically employed as a first-line treatment to manage the acute inflammatory phase of the disease.[1] While glucocorticoids can reduce inflammation and improve some symptoms like swelling and redness, they are associated with a host of systemic side effects. More importantly, their efficacy in reversing the underlying tissue remodeling is limited, leading to what is described as "inadequate improvement in proptosis".[1] Second-line treatments, such as other immunomodulators or orbital radiotherapy, also demonstrate limited effectiveness and carry their own risk profiles.[1] Once the disease enters an inactive, fibrotic phase, patients are often left with surgical options, such as orbital decompression or strabismus surgery, to address residual proptosis and diplopia.[11]

This therapeutic landscape has created a profound and long-standing unmet medical need, particularly within China, where there are currently no approved targeted therapies for TED.[3] This situation represents what has been described as a "more than six-decade dearth of innovative treatments for TED in China".[2] The failure of the existing standard of care to adequately address proptosis—the most disfiguring and psychologically burdensome aspect of the disease—is a critical therapeutic gap. Therefore, the development of a therapy that can specifically and effectively target the pathological mechanisms driving proptosis represents not merely an incremental advance but a potential paradigm shift in the management of TED for Chinese patients.

Furthermore, while targeted therapies like teprotumumab have become available in other markets, their high cost and limited accessibility have made them prohibitive for many patients globally.[14] This economic barrier reinforces the strategic importance of a domestically developed agent in China. The opportunity for IBI311 is therefore twofold: to provide a clinically superior alternative to glucocorticoids and to offer an accessible and affordable targeted treatment within the Chinese healthcare system. This positions IBI311 not only as a clinical innovation but also as a crucial health-economic solution for a significant patient population.

IBI311 - Profile of a Targeted Therapeutic

Drug Identity and Development

IBI311 is a recombinant human monoclonal antibody (mAb) specifically designed to target and inhibit the insulin-like growth factor 1 receptor (IGF-1R).[1] The drug was developed by Innovent Biologics, a biopharmaceutical company based in China, with a focus on addressing diseases with significant unmet needs within the country and globally.[2]

A defining characteristic of IBI311 is that it possesses an amino acid sequence identical to that of teprotumumab, the first-in-class IGF-1R inhibitor approved in the United States.[19] However, it is reported to have a different dosage form.[19] Despite the identical primary structure, which has led some to refer to it as a biosimilar [11], Innovent has pursued a standalone development pathway. The company has consistently positioned IBI311 as a novel therapeutic candidate and has submitted a full New Drug Application (NDA) to Chinese regulators, rather than pursuing an abbreviated biosimilar approval pathway.[1] This strategic decision is significant, as it allows Innovent to leverage the extensive clinical and biological validation of the IGF-1R target established by teprotumumab, thereby de-risking the fundamental scientific hypothesis of the program. Concurrently, by seeking approval as a novel biologic in China, Innovent can establish IBI311 as a unique brand with full pricing and commercial autonomy, aiming to define it as the pioneering therapy of its class within the domestic market. The reference to a "different dosage form" remains an important, though not fully elaborated, detail. While the clinical trial administration was intravenous and followed a schedule similar to teprotumumab's, this difference could pertain to formulation characteristics such as liquid versus lyophilized state, concentration, or stability, which may offer logistical or handling advantages in a clinical setting.

Mechanism of Action

The therapeutic rationale for IBI311 is directly rooted in the pathophysiology of TED. Its molecular target, the IGF-1R, is a transmembrane tyrosine kinase receptor that is pathologically overexpressed on orbital fibroblasts, B cells, and T cells in patients with TED.[7] IBI311 functions as a competitive antagonist at this receptor. By binding with high affinity to the extracellular domain of IGF-1R, it physically blocks the receptor from interacting with its natural ligands—primarily IGF-1 and IGF-2—as well as other agonistic autoantibodies that may be present in TED patients.[2]

This blockade of IGF-1R activation interrupts a critical signaling cascade that drives the disease process, leading to a multifaceted therapeutic effect:

1. Reduction of Inflammation: Inhibition of IGF-1R signaling leads to a downstream reduction in the expression and secretion of pro-inflammatory cytokines and chemokines by orbital fibroblasts. This dampens the autoimmune inflammatory response, helping to alleviate the signs of active inflammation such as orbital congestion, swelling, and edema.[2]
2. Inhibition of Tissue Remodeling: Activated orbital fibroblasts are responsible for the excessive production of GAGs like hyaluronic acid, which absorb water and contribute significantly to tissue volume expansion. By inhibiting the activation of these cells, IBI311 effectively suppresses GAG synthesis, addressing a core driver of proptosis.[2]
3. Reduction of Adipogenesis: The IGF-1R pathway is also implicated in the differentiation of orbital fibroblasts into mature adipocytes (fat cells). IBI311 inhibits this process of adipocyte cellularization, thereby limiting the expansion of orbital fat volume, which is another key contributor to the proptosis seen in TED.[7]

The collective result of these actions is a comprehensive therapeutic effect that not only controls the active inflammation of TED but also begins to reverse the pathological tissue remodeling. This leads to clinically meaningful improvements in the cardinal signs and symptoms of the disease, most notably proptosis and diplopia, as well as an overall reduction in disease activity.[7]

Clinical Evidence: The RESTORE-1 Trial and Supporting Studies

Early Stage Development (Phase I & II)

The clinical development program for IBI311 progressed through a systematic evaluation of its safety, tolerability, pharmacokinetics (PK), and efficacy.

The Phase I study (NCT05480597) was a single-dose escalation trial conducted in healthy Chinese volunteers. The primary objective was to assess the safety and tolerability of IBI311 administered via a single intravenous infusion. The results from this study were favorable, indicating that IBI311 was safe and well-tolerated across the dose levels tested. The most common treatment-emergent adverse events (AEs) were mild (Grade 1 or 2), transient, and typically resolved without intervention. Critically, no anti-drug antibodies (ADAs) were detected in any dose group, suggesting a low risk of immunogenicity. The PK profile obtained from this study supported the dose selection for subsequent patient trials.[7]

Building on this safety foundation, the Phase II study (NCT05795621) provided the first evidence of IBI311's efficacy in its target population. This was a multicenter, randomized, double-masked, placebo-controlled study designed to evaluate the drug in patients with moderately to severely active TED.[7] The study successfully met its primary endpoint at the 12-week assessment point, demonstrating a statistically significant improvement in proptosis. The proptosis responder rate (defined as a reduction of $\ge 2$ mm from baseline) was 59.1% in the IBI311 group compared to just 18.2% in the placebo group ($P=0.0309$).[7] The study also revealed that the therapeutic effect continued to increase with the full course of treatment. By week 24, the proptosis responder rate in the IBI311 arm had climbed to 72.7%, with patients achieving a mean reduction in proptosis of 3.37 mm from baseline. Furthermore, a remarkable 88.2% of patients in the treatment group achieved a diplopia response (improvement of $\ge 1$ grade) by week 24.[7] The safety profile in this patient population remained favorable and was consistent with the Phase I findings, with no treatment discontinuations due to AEs.[7] This strong proof-of-concept, demonstrating both rapid and escalating efficacy, provided a robust rationale for advancing IBI311 into the pivotal Phase III stage.

In-Depth Analysis of the RESTORE-1 Phase III Trial (CTR20223393)

The RESTORE-1 trial was the registrational Phase III study designed to definitively establish the efficacy and safety of IBI311 for the treatment of active TED in Chinese patients.

Study Design and Population: RESTORE-1 was a multicenter, randomized, double-masked, placebo-controlled trial conducted at 20 tertiary hospitals across China from May to December 2023.[14] The study enrolled 82 Chinese participants with active (Clinical Activity Score $\ge 3$), moderate-to-severe TED of recent onset ($\le 270$ days).[19] Participants were randomized in a 2:1 ratio to receive either IBI311 or a matching placebo.[19]

Intervention: The treatment regimen consisted of eight intravenous infusions administered once every three weeks over a 21-week period, with a final assessment at week 24.[19] The dosing schedule involved an initial dose of 10 mg/kg, followed by seven subsequent doses of 20 mg/kg.[18]

Efficacy Outcomes: The trial demonstrated a profound and statistically significant treatment effect, meeting its primary endpoint and most key secondary endpoints. The results showed that rapid effects were observable as early as week 6, with continued improvement through the 24-week study period.[11]

The primary endpoint was the proptosis responder rate in the study eye at week 24, defined as the percentage of subjects with a proptosis reduction of $\ge 2$ mm from baseline. An overwhelming majority of patients in the IBI311 group achieved this endpoint, with a response rate of 85.8%, compared to only 3.8% in the placebo group. This represented a treatment difference of 81.9 percentage points (95% CI, 69.8 to 93.9; $P <.001$), signifying a highly robust and clinically meaningful outcome.[16]

IBI311 also demonstrated superiority across key secondary endpoints related to overall disease improvement. The overall response rate, a composite measure requiring both a proptosis reduction of $\ge 2$ mm and a CAS reduction of $\ge 2$ points, was achieved by 80.2% of IBI311-treated patients versus 3.6% of placebo patients ($P <.001$). A return to an inactive disease state, defined as a CAS of 0 or 1, was seen in 83.5% of the IBI311 group compared to 16.6% of the placebo group ($P <.001$). The mean change from baseline in proptosis was -2.85 mm for IBI311 versus -0.02 mm for placebo ($P <.001$).[11]

One notable finding was the result for the diplopia response endpoint, defined as an improvement of at least one grade. While a higher percentage of patients in the IBI311 group responded (66.0%) compared to the placebo group (53.3%), this difference did not reach statistical significance ($P =.46$).[19] This result stands in contrast to the highly significant effects seen on other endpoints. The unusually high placebo response rate for diplopia (53.3%) may suggest significant subjective variability in this measurement, a characteristic of the specific patient population enrolled, or a potential limitation in the drug's effect on the complex neuromuscular dysfunction underlying diplopia compared to its effects on inflammation and tissue volume. While teprotumumab's pivotal trials demonstrated strong, significant effects on diplopia, this non-significant finding for IBI311 could represent a point of clinical differentiation and may temper the otherwise exceptional efficacy profile.

The consistency of the strong efficacy signal from the Phase II study to the larger Phase III RESTORE-1 trial provides a high degree of confidence in the drug's clinical profile and its reliability as a treatment.[6]

Endpoint (at Week 24)	IBI311 Group (n=52)	Placebo Group (n=26)	Difference	95% CI	P-value
Primary: Proptosis Response Rate ($\ge 2$ mm reduction)	85.8%	3.8%	81.9 pp	69.8 to 93.9	$<.001$
Secondary: Overall Response Rate ($\ge 2$ mm proptosis & $\ge 2$ CAS reduction)	80.2%	3.6%	76.6 pp	63.3 to 89.4	$<.001$
Secondary: CAS of 0 or 1	83.5%	16.6%	67.1 pp	49.4 to 84.8	$<.001$
Secondary: Mean Change in Proptosis from Baseline (mm)	-2.85	-0.02	-2.83 mm	-3.39 to -2.27	$<.001$
Secondary: Diplopia Response ($\ge 1$ grade improvement)	66.0%	53.3%	12.7 pp	N/A	.46

Safety and Tolerability Assessment

Overall Safety Profile from Clinical Program

Across its entire clinical development program, IBI311 has consistently demonstrated what investigators have described as a "favorable safety profile".[6] The data from Phase I, II, and III studies indicate that the majority of reported adverse events were mild or moderate in severity.[7] A key finding from the pivotal RESTORE-1 trial was the absence of any serious adverse events (SAEs) or deaths in the IBI311 treatment arm.[6] Furthermore, the Phase II study reported no treatment discontinuations resulting from adverse events, underscoring the drug's general tolerability in the patient population.[7]

Adverse Events of Special Interest (AESIs)

As an inhibitor of the IGF-1R, IBI311 is associated with a specific set of potential side effects inherent to its mechanism of action. These known class-effects, designated as adverse events of special interest (AESIs), were prospectively monitored in the clinical trials. The most common AESIs include infusion-related reactions, hearing impairment, hyperglycemia, muscle spasms, and gastrointestinal issues such as nausea or diarrhea.[11]

In the RESTORE-1 trial, all observed instances of these AESIs were reported to be mild or moderate in severity.[19] The overall conclusion from the trial investigators and the developing company is that IBI311 demonstrated "no new safety issues not identified in previous clinical trials" of IGF-1R inhibitors.[1] From a regulatory perspective, this statement signifies that the safety profile of IBI311 aligns with the known risks of its drug class, without introducing unexpected or novel toxicities.

Comparative Safety and Key Nuances

Despite the overall favorable assessment, a more nuanced analysis reveals important details regarding the safety profile of IBI311, particularly in comparison to teprotumumab. One analysis noted that while the safety profile is "somewhat comparable to teprotumumab," IBI311 was associated with "higher incidences of hearing impairment and menstrual disorder".[11] This observation presents a critical point for consideration. Hearing impairment is a well-documented and serious risk associated with teprotumumab, with post-marketing reports of permanent hearing loss leading to significant clinical concern and regulatory scrutiny in the U.S..[20] Therefore, any signal suggesting a potentially higher incidence of this specific AE with IBI311 warrants close attention.

This finding suggests that an identical amino acid sequence does not necessarily guarantee an identical safety profile. Subtle differences in manufacturing processes, protein glycosylation, or the "different dosage form" could potentially influence the drug's biological behavior and off-target effects. It also highlights the distinction between regulatory and clinical interpretations of safety data. While the observation of hearing loss is not a "new" or unexpected signal for this class of drug, a higher frequency of a known serious side effect is a highly relevant clinical and commercial factor. This underscores the importance of robust post-marketing surveillance and real-world evidence generation following IBI311's potential approval. Proactive patient monitoring, including baseline and on-treatment audiometric testing, will likely be a key component of responsible clinical practice with IBI311.

Adverse Event of Special Interest	Severity Reported in RESTORE-1	Notes
Infusion Reaction	Mild or Moderate	Consistent with known risks for intravenous monoclonal antibodies.
Hearing Impairment	Mild or Moderate	A key AE for the IGF-1R inhibitor class. One source suggests a higher incidence compared to teprotumumab.11
Hyperglycemia	Mild or Moderate	Expected class effect due to IGF-1R's role in glucose metabolism. Requires monitoring, especially in diabetic patients.
Muscle Spasm	Mild or Moderate	Common AE associated with IGF-1R inhibition.
Nausea or Diarrhea	Mild or Moderate	Common gastrointestinal side effects observed with this class of therapy.

Regulatory Trajectory and Market Access in China

New Drug Application (NDA) Submission and Acceptance

Leveraging the robust and positive data from the RESTORE-1 Phase III trial, Innovent Biologics moved swiftly to seek regulatory approval. The company prepared and submitted a New Drug Application (NDA) for IBI311 for the treatment of Thyroid Eye Disease to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).[1] In a significant milestone for the program, the NMPA officially accepted the NDA for formal review in May 2024.[1]

Priority Review Designation and Implications

Shortly after accepting the application, the CDE granted Priority Review designation to the IBI311 NDA.[1] This designation is a powerful indicator of the regulator's view of the drug's potential. Priority Review is reserved for therapies that are deemed to have significant clinical advantages over existing treatments or that address a serious condition with a significant unmet medical need. The decision to grant this status serves as a strong regulatory validation of the entire clinical and strategic thesis behind IBI311. It confirms that the NMPA recognizes the inadequacy of current TED treatments in China and views IBI311 as a potentially substantial improvement for patients. This action significantly increases the probability of a favorable approval decision and has the potential to shorten the regulatory review timeline, accelerating the drug's path to market.

The acceptance of the NDA makes IBI311 the first anti-IGF-1R antibody to reach this advanced regulatory stage in China, positioning it for a critical first-mover advantage in this therapeutic class.[1] The entire development and regulatory process for IBI311 exemplifies a growing trend of "in-China for-China" biopharmaceutical innovation. By conducting pivotal trials exclusively in Chinese patients and tailoring its regulatory strategy for the NMPA, Innovent has created a program that is vertically integrated within the Chinese healthcare ecosystem. This approach not only addresses a specific domestic unmet need but also serves as a model for how local companies can develop and commercialize innovative medicines for their own market, a trend with significant long-term implications for the global pharmaceutical landscape.

Competitive Landscape and Future Perspectives

The Benchmark: Teprotumumab (Tepezza)

The competitive landscape for TED therapies is defined by the presence of teprotumumab (brand name Tepezza), which is marketed by Amgen following its acquisition of Horizon Therapeutics. As the first and, to date, only therapy approved by the U.S. Food and Drug Administration (FDA) for TED, Tepezza has established IGF-1R inhibition as the gold standard targeted therapy for the disease.[20] Its rapid uptake and blockbuster sales figures have unequivocally validated the clinical utility and commercial potential of this mechanism of action.[29] However, Tepezza's market position is not unassailable. Its profile is characterized by several factors that create opportunities for competitors: intravenous (IV) administration, which requires visits to an infusion center; a high price point; and a significant safety concern related to hearing impairment, which has garnered considerable attention post-launch.[21]

The Evolving TED Pipeline - Next-Generation Competitors

IBI311 is poised to enter the Chinese market at a strategically advantageous time. It will likely launch well ahead of any next-generation competitors, affording it a crucial window of several years to establish itself as the standard of care, build physician experience, and secure market access. This incumbency will be a formidable advantage against later entrants.

However, the global TED pipeline is dynamic and focused on addressing the limitations of first-generation IV therapies. The long-term competitive threat to IBI311 will come from therapies offering improved convenience and alternative mechanisms of action. The entire field is moving decisively away from hospital-based infusions. The development of subcutaneous and oral formulations represents a direct challenge to the primary logistical and patient-burden weaknesses of both Tepezza and IBI311. While IBI311 is set for initial market dominance in China, its long-term success will be contingent on Innovent's life-cycle management strategy, including the potential development of a follow-on product with a more convenient administration profile.

Drug	Developer(s)	Target / Mechanism of Action	Route of Administration	Development Status
Tepezza (teprotumumab)	Amgen (Horizon)	IGF-1R Inhibitor	Intravenous (IV)	Marketed (U.S., others)
IBI311	Innovent Biologics	IGF-1R Inhibitor	Intravenous (IV)	NDA under review (China)
Veligrotug (VRDN-001)	Viridian Therapeutics	IGF-1R Inhibitor	Intravenous (IV)	Phase III
VRDN-003	Viridian Therapeutics	IGF-1R Inhibitor (half-life extended)	Subcutaneous (SC)	Phase III
Lonigutamab	Acelyrin / ValenzaBIO	IGF-1R Inhibitor	Subcutaneous (SC)	Phase I/II
Linsitinib	Sling Therapeutics	IGF-1R Inhibitor (small molecule)	Oral	Phase II/III
Batoclimab	Immunovant	FcRn Antagonist	Subcutaneous (SC)	Phase III
Efgartigimod	Argenx	FcRn Antagonist	Subcutaneous (SC)	Phase III
Satralizumab (Enspryng)	Roche / Chugai	IL-6R Inhibitor	Subcutaneous (SC)	Phase III

Strategic Synthesis and Concluding Remarks

Consolidated Value Proposition

IBI311 has emerged from its clinical development program as a highly effective and promising therapeutic agent for patients with active, moderate-to-severe Thyroid Eye Disease. Supported by robust data from the pivotal Phase III RESTORE-1 trial, its value proposition is clear and compelling. The drug offers profound and rapid reductions in proptosis and overall disease activity, addressing the most significant unmet need in the current TED treatment paradigm in China. Its benefit-risk profile appears favorable, with the majority of adverse events being mild to moderate and no new, unexpected safety signals identified for its class. However, vigilance regarding known class-related side effects, particularly the potential for hearing impairment, will be essential in clinical practice.

Expert Opinion and Outlook

IBI311 is strategically positioned to fundamentally alter the standard of care for TED in China. Upon its anticipated approval, it is expected to be rapidly adopted by ophthalmologists and endocrinologists, capturing a significant and previously untapped market. Its success is built on a foundation of strong clinical evidence generated within the target patient population and a regulatory pathway accelerated by the NMPA's recognition of its importance.

The drug benefits from a critical first-mover advantage. It will enter the Chinese market in a therapeutic vacuum, free from direct competition from other targeted agents for a period of several years. This provides Innovent with a unique opportunity to establish IBI311 as the definitive treatment for proptosis-dominant TED, building a strong base of physician experience and market penetration.

In the long term, the competitive landscape will evolve. The global trend toward more convenient subcutaneous and oral therapies represents the most significant future threat to IBI311's market share. Therefore, while IBI311 stands as a landmark achievement for Innovent and a testament to the growing capabilities of the Chinese biopharmaceutical industry, sustained leadership in the TED market will require continued innovation. The key strategic imperative for Innovent will be to execute a successful market launch while simultaneously planning a life-cycle management strategy to address the inevitable shift toward greater patient convenience in the latter half of this decade.

Works cited

1. Innovent's IBI311 Drug Application for Thyroid Eye Disease ..., accessed November 2, 2025, https://synapse.patsnap.com/article/innovents-ibi311-drug-application-for-thyroid-eye-disease-accepted-by-nmpa
2. Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease - PR Newswire, accessed November 2, 2025, https://www.prnewswire.com/news-releases/innovent-announces-the-new-drug-application-of-ibi311-igf-1r-antibody-has-been-accepted-by-the-nmpa-of-china-for-thyroid-eye-disease-302150666.html
3. Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease - PR Newswire, accessed November 2, 2025, https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-phase-3-study-restore-of-ibi311-anti-igf-1r-monoclonal-antibody-in-patients-with-thyroid-eye-disease-301817782.html
4. Thyroid Eye Disease Treatment Market - Price, Size, Share & Growth, accessed November 2, 2025, https://www.coherentmarketinsights.com/market-insight/thyroid-eye-disease-treatment-market-3538
5. Innovent's Phase 3 RESTORE-1 Study of IBI311 for Thyroid Eye Disease Hits Key Goal, Eyes NMPA Filing - Patsnap Synapse, accessed November 2, 2025, https://synapse.patsnap.com/blog/innovents-phase-3-restore-1-study-of-ibi311-for-thyroid-eye-disease-hits-key-goal-eyes-nmpa-filing
6. Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA - PR Newswire, accessed November 2, 2025, https://www.prnewswire.com/news-releases/innovent-announces-primary-endpoint-met-in-the-phase-3-clinical-trial-restore-1-of-ibi311-anti-igf-1r-antibody-in-treating-thyroid-eye-disease-and-plans-to-submit-nda-to-the-nmpa-302065096.html
7. Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 - BioSpace, accessed November 2, 2025, https://www.biospace.com/innovent-released-the-results-of-two-clinical-studies-of-ibi311-an-anti-igf-1r-monoclonal-antibody-in-oral-presentations-at-the-asia-pacific-academy-of-ophthalmology-congress-and-international-congress-of-endocrinology-2024
8. Innovent's NDA for TED Treatment Granted Priority Review in China, accessed November 2, 2025, https://ophthalmologybreakingnews.com/innovents-nda-for-ted-granted-priority-review-in-china
9. Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease - BioSpace, accessed November 2, 2025, https://www.biospace.com/innovent-announces-first-participant-dosed-in-phase-3-study-restore-of-ibi311-anti-igf-1r-monoclonal-antibody-in-patients-with-thyroid-eye-disease
10. China's First Targeted Biologic Therapy: Prof. Xianqun Fan's Team Announces Phase III Clinical Results of Domestic IGF-1R Monoclonal Antibody for Thyroid Eye Disease-Shanghai Jiao Tong University School of Medicine, accessed November 2, 2025, https://www.shsmu.edu.cn/english/info/1021/5297.htm
11. Biosimilar Agent Promising as a Newer Alternative for TED Treatment - Review of Optometry, accessed November 2, 2025, https://www.reviewofoptometry.com/news/article/biosimilar-agent-promising-as-a-newer-alternative-for-ted-treatment
12. IBI311 Achieves Phase 3 Success in Thyroid Eye Disease Trial with NDA Submission Planned - Patsnap Synapse, accessed November 2, 2025, https://synapse.patsnap.com/article/ibi311-achieves-phase-3-success-in-thyroid-eye-disease-trial-with-nda-submission-planned
13. China's NMPA Accepts Innovent's NDA for IBI311 Antibody to Treat Thyroid Eye Disease, accessed November 2, 2025, https://synapse.patsnap.com/blog/chinas-nmpa-accepts-innovents-nda-for-ibi311-antibody-to-treat-thyroid-eye-disease
14. Innovent Biologics' RESTORE-1 of IBI311 achieves primary endpoint in phase 3 trial to treat thyroid eye disease; plans to submit NDA to China NMPA, accessed November 2, 2025, https://www.pharmabiz.com/NewsDetails.aspx?aid=166516&sid=2
15. Innovent's IBI311 Clears Phase 3 Hurdle for Thyroid Eye Disease with Promising Results, accessed November 2, 2025, https://www.biopharmaapac.com/news/31/4399/innovents-ibi311-clears-phase-3-hurdle-for-thyroid-eye-disease-with-promising-results.html
16. Innovent Biologics meets primary endpoint for Phase 3 clinical trial, plans to submit NDA, accessed November 2, 2025, https://www.optometrytimes.com/view/innovent-biologics-meets-primary-endpoint-for-phase-3-clinical-trial-plans-to-submit-nda
17. Innovent's Phase III thyroid eye disease trial meets primary endpoint, accessed November 2, 2025, https://www.clinicaltrialsarena.com/news/innovent-thyroid-eye-disease-trial/
18. First patient dosed in phase 2, China-based TED trial, accessed November 2, 2025, https://glance.eyesoneyecare.com/stories/2023-05-10/first-patient-dosed-in-phase-2-ted-trial/
19. IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial - PubMed, accessed November 2, 2025, https://pubmed.ncbi.nlm.nih.gov/41066129/
20. Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therapeutic Strategies - PubMed Central, accessed November 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12347536/
21. Thyroid Eye Disease (TED) | Competitive Intelligence, accessed November 2, 2025, https://www.datamintelligence.com/strategic-insights/thyroid-eye-disease-ted
22. Emerging therapies in the medical management of thyroid eye disease - Frontiers, accessed November 2, 2025, https://www.frontiersin.org/journals/ophthalmology/articles/10.3389/fopht.2023.1295902/full
23. Treatment for Thyroid Eye Disease | TEPEZZA® (teprotumumab-trbw), accessed November 2, 2025, https://www.tepezza.com/
24. Innovent Announces NMPA Acceptance of NDA for IBI311 (IGF-1R Antibody) to Treat Thyroid Eye Disease in China - Pharma Focus Asia, accessed November 2, 2025, https://www.pharmafocusasia.com/news/innovent-announces-nmpa-acceptance-of-nda-for-ibi311-igf-1r-antibody-to-treat-thyroid-eye-disease-in-china
25. Chinese Regulators Accept NDA from Innovent for IBI311 in Thyroid Eye Disease, accessed November 2, 2025, https://www.market-scope.com/pages/news/7662/chinese-regulators-accept-nda-from-innovent-for-ibi311-in-thyroid-eye-disease
26. Innovent Biologics' New Drug for Thyroid Eye Disease Granted Priority Review in China, accessed November 2, 2025, https://biopharmaapac.com/news/41/4785/innovent-biologics-new-drug-for-thyroid-eye-disease-granted-priority-review-in-china.html
27. 4 Late-Stage Thyroid Eye Disease Treatments - DelveInsight, accessed November 2, 2025, https://www.delveinsight.com/blog/4-late-stage-thyroid-eye-disease-treatments
28. A Bird's Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease - Certara, accessed November 2, 2025, https://www.certara.com/blog/a-birds-eye-view-on-rare-diseases-key-drug-development-considerations-for-thyroid-eye-disease/
29. Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win, accessed November 2, 2025, https://www.fiercebiotech.com/biotech/innovents-tempezza-rival-one-step-closer-chinese-approval-after-phase-3-win